Category Research

U.S. FDA Conducts Inspection of Lupin’s Dabhasa Facility, Finds No Observations

Lupin Limited, a leading global pharmaceutical company, announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a Good Manufacturing Practice (GMP) Inspection of its Active Pharmaceutical Ingredient (API) manufacturing facility situated in Dabhasa, India.…

Read MoreU.S. FDA Conducts Inspection of Lupin’s Dabhasa Facility, Finds No Observations

Baxter Broadens Pharmaceutical Portfolio with Fresh Injectable Offerings in the U.S.

Baxter International Inc. (NYSE:BAX), renowned globally for its excellence in injectables, anesthesia, and drug compounding, has unveiled a significant expansion of its Pharmaceuticals portfolio with the introduction of five new injectable products in the United States. Alok Sonig, Executive Vice…

Read MoreBaxter Broadens Pharmaceutical Portfolio with Fresh Injectable Offerings in the U.S.

FDA Grants Roche Breakthrough Device Designation for Blood Test Advancing Early Alzheimer’s Disease Detection

Roche (SIX: RO, ROG; OTCQX: RHHBY) disclosed today that its Elecsys pTau217 assay has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Developed in collaboration with Eli Lilly and Company, this blood test aims to…

Read MoreFDA Grants Roche Breakthrough Device Designation for Blood Test Advancing Early Alzheimer’s Disease Detection

Orion Research Assistants Striving to Combat Cancer and Alleviate Pain: “Our Breakthrough Discovery Holds Promise for Shaping Future Research

Mira Leppänen-Mattelmäki, a Research Associate in Orion’s pain team, finds her greatest motivation in the potential impact their work may have on patients. For Minna Vuorenmaa, a Research Assistant in the cancer research team, the meaningfulness of aiding patients fuels…

Read MoreOrion Research Assistants Striving to Combat Cancer and Alleviate Pain: “Our Breakthrough Discovery Holds Promise for Shaping Future Research

Progress in Clinical Development of Efgartigimod for Primary Sjogren’s Disease by Argenx

A global immunology company dedicated to enhancing the lives of individuals grappling with severe autoimmune conditions has unveiled its intention to propel the development of efgartigimod into Phase 3 for adults diagnosed with primary Sjogren’s disease (SjD), following an in-depth…

Read MoreProgress in Clinical Development of Efgartigimod for Primary Sjogren’s Disease by Argenx

AbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions

AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused on developing novel oral therapeutics for patients with autoimmune diseases.…

Read MoreAbbVie’s Acquisition of Landos Biopharma Bolsters its Reach in Inflammatory and Autoimmune Conditions